One Year Outcomes of Zilver PTX Versus Eluvia for Femoropopliteal Disease in Real-World Practice: REALDES Study

Abstract

Purpose:

This multicenter, prospective, observational study aimed to compare Zilver PTX and Eluvia stents in real-world settings for treating femoropopliteal lesions as the differences in the 1-year outcomes of these stents have not been elucidated.

Materials and Methods:

Overall, 200 limbs with native femoropopliteal artery disease were treated with Zilver PTX (96 limbs) or Eluvia (104 limbs) at 8 Japanese hospitals between February 2019 and September 2020. The primary outcome measure of this study was primary patency at 12 months, defined as a peak systolic velocity ratio of ≤2.4, without clinically-driven target lesion revascularization (TLR) or stenosis ≤50% based on angiographic findings.

Results:

The baseline clinical and lesion characteristics of Zilver PTX and Eluvia groups were roughly comparable (of all limbs analyzed, approximately 30% presented with critical limb-threatening ischemia, approximately 60% presented with Trans-Atlantic Inter-Society Consensus II C-D, and approximately half had total occlusion), except for the longer lesion lengths in the Zilver PTX group (185.7±92.0 mm vs 160.0±98.5 mm, p=0.030). The Kaplan–Meier estimates of primary patency at 12 months were 84.9% and 88.1% for Zilver PTX and Eluvia, respectively (log-rank p=0.417). Freedom from clinically-driven TLR rates were 88.8% and 90.9% for Zilver PTX and Eluvia, respectively (log-rank p=0.812).

Conclusions:

The results of the Zilver PTX and Eluvia stents were not different regarding primary patency and freedom from clinically-driven TLR at 12 months after treating patients with femoropopliteal peripheral artery disease in real-world settings.

Clinical Impact

This is the first study to reveal that the Zilver PTX and Eluvia have similar results in real-world practice when the proper vessel preparation is performed. However, the type of restenosis in the Eluvia stent may differ from that in the Zilver PTX stent. Therefore, the results of this study may influence the selection of DES for femoropopliteal lesions in routine clinical practice.

Keywords

Zilver PTX Eluvia stent femoropopliteal lesions drug-eluting stent real-world settings vessel preparation

Get full access to this article

View all access options for this article.

References

Dake

Ansel

Jaff

, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61:2417–2427.

Bosiers

Peeters

Tessarek

, et al. The Zilver® PTX® single arm study: 12-month results from the TASC C/D lesion subgroup. J Cardiovasc Surg (Torino). 2013;54(1):115–122.

Yokoi

Ohki

Kichikawa

, et al. Zilver PTX post-market surveillance study of paclitaxel-eluting stents for treating femoropopliteal artery disease in Japan: 12-month results. J Am Coll Cardiol Intv. 2016;9:271–277.

Dake

Ansel

Jaff

, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483.

Müller-Hülsbeck

Keirse

Zeller

, et al. Twelve-month results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease. J Endovasc Ther. 2016;23(5):701–707.

Bisdas

Beropoulis

Argyriou

, et al. 1-year all-comers analysis of the Eluvia drug-eluting stent for long femoropopliteal lesions after suboptimal angioplasty. J Am Coll Cardiol Intv. 2018;11:957–966.

Kichikawa

Ichihashi

Yokoi

, et al. Zilver PTX post-market surveillance study of paclitaxel-eluting stents for treating femoropopliteal artery disease in Japan: 2-year results. Cardiovasc Intervent Radiol. 2019;42(3):358–364.

Golzar

Soga

Babaev

, et al. Effectiveness and safety of a paclitaxel-eluting stent for superficial femoral artery lesions up to 190 mm: one-year outcomes of the single-arm IMPERIAL long lesion substudy of the Eluvia drug-eluting stent. J Endovasc Ther. 2020;27(2):296–303.

Iida

Takahara

Soga

, et al. 1-year outcomes of fluoropolymer-based drug-eluting stent in femoropopliteal practice. J Am Coll Cardiol Intv. 2022;15:630–638.

10.

Iida

Takahara

Soga

, et al. 1-year results of the Zephyr Registry (Zilver PTX for the femoral artery and proximal popliteal artery): predictors of restenosis. JACC Cardiovasc Interv. 2015;8(8):1105–1112.

11.

Gray

Keirse

Soga

, et al. A polymer- coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (Imperial): a randomised, non-inferiority trial. Lancet. 2018;392:1541–1551.

12.

Müller-Hülsbeck

Benko

Soga

, et al. Two-year efficacy and safety results from the IMPERIAL randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer- free drug-coated stent. Cardiovasc Intervent Radiol. 2021;44(3):368–375.

13.

Rocha-Singh

Zeller

Jaff

MR.

Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83:E212–E220.

14.

Patel

Conte

Cutlip

, et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol. 2015;65:931–941.

15.

Norgren

Hiatt

Dormandy

, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(suppl 1):S1–75.

16.

Davaine

Querat

Kaladji

, et al. Treatment of TASC C and D femoropoliteal lesions with paclitaxel eluting stents: 12 month results of the STELLA-PTX registry. Eur J Vasc Endovasc Surg. 2015;50(5):631–637.

17.

Miki

Fujii

Shibuya

, et al. Impact of stent diameter on vascular response after self-expanding paclitaxel-eluting stent implantation in the superficial femoral artery. J Cardiol. 2017;70(4):346–352.

18.

Sakamoto

Torii

Jinnouchi

, et al. Vascular response of a polymer-free paclitaxel-coated stent (Zilver PTX) versus a polymer-coated paclitaxel-eluting stent (Eluvia) in healthy swine femoropopliteal arteries. J Vasc Interv Radiol. 2021;32(6):792–801.e5.